Generated by AI
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company focused on developing targeted cancer therapies and imaging agents. The company’s work centers on its proprietary phospholipid drug conjugate platform, which is designed to deliver therapeutic payloads directly to cancer cells while limiting exposure to healthy tissue. Its current portfolio includes radioconjugate and other oncology programs aimed at hematologic malignancies and solid tumors, along with imaging applications that support cancer detection and treatment planning. Cellectar Biosciences also pursues commercialization and research collaborations to advance its drug candidates through development. Headquartered in Florham Park, New Jersey, Cellectar Biosciences operates as a specialized cancer-focused company within the biopharmaceutical sector.
Website100 Campus Drive
Florham Park, NJ, 07932
United States
The latest articles about CLRB.
Detailed price information for Arm Holdings Plc ADR (ARM-Q) from The Globe and Mail including charting and trades.
Summary of Jul 15's posts. Generated by AI.
Summary of May 6's posts. Generated by AI.
Presented updated data at the International Workshop for Waldenström Macroglobulinemia (IWWM) supporting the planned accelerated approval strategy...
Summary of May 5's posts. Generated by AI.
Summary of May 6's posts. Generated by AI.
Investors talking about CLRB also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.